CompletedPHASE1, PHASE2NCT04644627
Topical Gentamicin Nonsense Suppression Therapy of EB
Studying Inherited epidermolysis bullosa
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Oslo University Hospital
- Principal Investigator
- Øystein Sandanger, MD, PhDSection of Dermatology, OUS
- Intervention
- Gentamicin Sulfate(drug)
- Enrollment
- 4 target
- Eligibility
- All sexes
- Timeline
- 2020 – 2022
Study locations (1)
- Oslo University Hospital, Oslo, Norway
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04644627 on ClinicalTrials.govOther trials for Inherited epidermolysis bullosa
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT05838092Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)RHEACELL GmbH & Co. KG
- ACTIVE NOT RECRUITINGPHASE3NCT05464381Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)RHEACELL GmbH & Co. KG
- ACTIVE NOT RECRUITINGNANCT05248503Impact of Complex Care Training of Hereditary Epidermolysis Bullosa on Caregiver Burden (FIREB)Assistance Publique - Hôpitaux de Paris
- RECRUITINGNANCT05954416FARD (RaDiCo Cohort) (RaDiCo-FARD)Institut National de la Santé Et de la Recherche Médicale, France